FDA Approves Supplementary Treatment For Parkinson’s Disease “Off” Episodes
https://pixabay.com/en/approved-pass-ok-approval-symbol-1726357/

FDA Approves Supplementary Treatment For Parkinson’s Disease “Off” Episodes

A recent publication from the US Food and Drug Administration announced the regulatory authority's approval of Nourianz (generic name istradefylline) for Parkinson's patients during "off" episodes. "Off" episodes are windows…

Continue Reading FDA Approves Supplementary Treatment For Parkinson’s Disease “Off” Episodes
The Center for Chronic Illness’s Support Groups: A Resource for Community and Support for Rare Disease Patients
rawpixel / Pixabay

The Center for Chronic Illness’s Support Groups: A Resource for Community and Support for Rare Disease Patients

The Center for Chronic Illness is a nonprofit group that is based out of Seattle, Washington. The goals of this organization include the provision of support and educational resources to…

Continue Reading The Center for Chronic Illness’s Support Groups: A Resource for Community and Support for Rare Disease Patients

Experimental Treatment for Facioscapulohumeral Muscular Dystrophy has Disappointing Results but May Still Benefit Charcot-Marie-Tooth Disease

The Bad News Unfortunately, it has recently been announced that an experimental treatment for facioscapulohumeral muscular dystrophy (FSHD) will not be continuing on in clinical trials. This is because the…

Continue Reading Experimental Treatment for Facioscapulohumeral Muscular Dystrophy has Disappointing Results but May Still Benefit Charcot-Marie-Tooth Disease
A Potential Treatment for Idiopathic Pulmonary Fibrosis Earns Orphan Drug Designation
Pexels / Pixabay

A Potential Treatment for Idiopathic Pulmonary Fibrosis Earns Orphan Drug Designation

According to a story from Financial Buzz, the biotherapeutics company Bellerophon Therapeutics Inc. has recently announced that it has earned Orphan Drug designation from the US Food and Drug Administration…

Continue Reading A Potential Treatment for Idiopathic Pulmonary Fibrosis Earns Orphan Drug Designation
When is a yes a yes, and when is it an ‘I can’t say no’?  For Persons with Disabilities, Consent is Complicated
Catkin / Pixabay

When is a yes a yes, and when is it an ‘I can’t say no’? For Persons with Disabilities, Consent is Complicated

Consent is a concept back under discussion in modern conversations as we readdress what it means to cross the line. Consent is no longer seen in the black and white…

Continue Reading When is a yes a yes, and when is it an ‘I can’t say no’? For Persons with Disabilities, Consent is Complicated
Study Links Age of Onset and Year of Birth to Delayed Diagnosis for Hereditary Angioedema
mohamed_hassan / Pixabay

Study Links Age of Onset and Year of Birth to Delayed Diagnosis for Hereditary Angioedema

According to a study recently published in Allergy and Asthma Proceedings, certain risk factors may increase an individual's likelihood of receiving a late diagnosis for hereditary angioedema. Hereditary angioedema is…

Continue Reading Study Links Age of Onset and Year of Birth to Delayed Diagnosis for Hereditary Angioedema
This Doctor’s Life Changed Forever When His Son Was Born With Spinal Muscular Atrophy
Movidagrafica / Pixabay

This Doctor’s Life Changed Forever When His Son Was Born With Spinal Muscular Atrophy

According to a story from medicalxpress.com, Dr. Nathan Hoot is an emergency medical physician, but his role as a doctor doesn't entirely end when he leaves the hospital because his…

Continue Reading This Doctor’s Life Changed Forever When His Son Was Born With Spinal Muscular Atrophy